WO2020130478A1 - Composition antiallergique, de soulagement de dermatite atopique ou de régénération de la peau contenant de la jasmone en tant que principe actif - Google Patents

Composition antiallergique, de soulagement de dermatite atopique ou de régénération de la peau contenant de la jasmone en tant que principe actif Download PDF

Info

Publication number
WO2020130478A1
WO2020130478A1 PCT/KR2019/017488 KR2019017488W WO2020130478A1 WO 2020130478 A1 WO2020130478 A1 WO 2020130478A1 KR 2019017488 W KR2019017488 W KR 2019017488W WO 2020130478 A1 WO2020130478 A1 WO 2020130478A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
active ingredient
atopic dermatitis
jasmone
jasmon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2019/017488
Other languages
English (en)
Korean (ko)
Inventor
박태선
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Botanicsens
Original Assignee
Botanicsens
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Botanicsens filed Critical Botanicsens
Publication of WO2020130478A1 publication Critical patent/WO2020130478A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q13/00—Formulations or additives for perfume preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/304—Foods, ingredients or supplements having a functional effect on health having a modulation effect on allergy and risk of allergy
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat

Definitions

  • the present invention relates to an anti-allergic, atopic dermatitis improvement, or skin regeneration composition
  • Jasmone as an active ingredient
  • an allergic disease comprising Jasmon or a pharmaceutically acceptable salt thereof as an active ingredient.
  • a composition for preventing or treating atopic dermatitis, skin wound healing or promoting skin regeneration is also known as a topical composition.
  • atopy has not been identified, but it is not limited to one factor, such as family history, changes in diet, allergen penetration, or abnormality of the skin protective layer. It mainly affects infants and toddlers and may persist or begin in adulthood. The typical symptoms of atopy appear on the hands, scalp, face, neck, and elbows, but there are differences in the appearance of each period. Symptoms of infancy are skin roughness and dryness, dermatitis on the outside of the limbs, and often appear on the cheeks or forehead. In childhood, it appears mainly on the folds of the arms, legs and neck rather than the face, and the skin becomes dry. In puberty and adulthood, symptoms of thickening of the skin in areas such as the face or hands appear.
  • Topical steroids topical immunomodulators, systemic steroids, systemic immunosuppressants and antihistamines are used as therapeutic agents for atopic drugs.
  • Topical steroids are used when atopic symptoms are severe and are the most basic method of managing bacterial or viral infections.
  • steroids were introduced in 1950 and have been used for many years, their long-term use is limited due to skin safety and tolerance problems, depending on the frequency, concentration, and duration of use.
  • skin side effects such as skin atrophy, telangiectasia and steroid acne, as well as potential HPA (hypothalamic-pituitary-adrenal) inhibition and Cushing's syndrome Be careful when using it because it can cause side effects.
  • HPA hypothalamic-pituitary-adrenal
  • the topical immunomodulators tacrolimus and pimecrolimus are known to be used over a long period of time for the purpose of preventing recurrence of the lesion because they are relatively unlikely to have side effects even when used for a long time, unlike conventional topical steroids. It is suitable for use as a treatment and maintenance therapy. However, tacrolimus can cause side effects such as decreased kidney function, tremors, and hair loss, and pimecrolimus can cause serious side effects such as skin cancer and lymphoma, as well as acne and burning. When steroids are exacerbated in the acute phase, topical immunomodulators are suitable for use as mild atopy treatment and maintenance therapy, but the safety of side effects is not yet secured, and there is an urgent need for alternative supplements.
  • the applicant has tried to develop a material that is effective in alleviating the symptoms of atopic dermatitis with fewer side effects, and as a result, confirms that jasmon relieves atopic symptoms and improves the inflammatory response, and anti-allergic, wound
  • the present invention was completed by confirming that there is a healing effect.
  • An object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of allergic diseases or atopic dermatitis comprising Jasmone or a pharmaceutically acceptable salt thereof as an active ingredient.
  • Another object of the present invention is to provide a composition for the prevention or improvement of allergic disease or atopic dermatitis comprising jasmine or a salt thereof as an active ingredient.
  • Another object of the present invention is to provide a pharmaceutical composition for promoting skin wound healing or skin regeneration, which includes jasmon or a pharmaceutically acceptable salt thereof as an active ingredient.
  • Another object of the present invention is to provide a quasi-drug composition for promoting skin wound healing or skin regeneration, which includes jasmon or a pharmaceutically acceptable salt thereof as an active ingredient.
  • Another object of the present invention is to provide a cosmetic composition for promoting skin wound healing or skin regeneration, which includes jasmon or a pharmaceutically acceptable salt thereof as an active ingredient.
  • the present invention is to solve the above-mentioned problems, and provides a pharmaceutical composition for preventing or treating allergic disease or atopic dermatitis comprising Jasmone or a pharmaceutically acceptable salt thereof as an active ingredient.
  • the allergic disease is edema, anaphylaxis, allergic rhinitis, asthma, allergic conjunctivitis, allergic dermatitis, contact Sex dermatitis, urticaria, pruritus, insect allergies, food allergies and drug allergies may be selected from the group consisting of, but is not limited to.
  • the active ingredient is IL-4 (Interleukin-4), IL-13, TNF- ⁇ (tumor necrosis factor-alpha), IL-1 ⁇ , IL-6 or IL-8 expression
  • IL-4 Interleukin-4
  • IL-13 TNF- ⁇ (tumor necrosis factor-alpha)
  • TNF- ⁇ tumor necrosis factor-alpha
  • IL-1 ⁇ IL-6
  • IL-8 expression By reducing, it can exhibit an anti-allergic effect, a preventive or therapeutic effect of atopic dermatitis.
  • the present invention provides a composition for preventing or improving allergic disease or atopic dermatitis comprising jasmon or a salt thereof as an active ingredient.
  • the composition may be a health functional food composition, a cosmetic composition, or a fragrance composition.
  • the present invention provides a pharmaceutical composition for promoting skin wound healing or skin regeneration, comprising Jasmon or a pharmaceutically acceptable salt thereof as an active ingredient.
  • the present invention provides a quasi-drug composition for promoting skin wound healing or skin regeneration, which includes Jasmon or a pharmaceutically acceptable salt thereof as an active ingredient.
  • the present invention provides a cosmetic composition for promoting skin wound healing or skin regeneration, which includes jasmon or a salt thereof as an active ingredient.
  • the present invention provides a method for preventing or treating allergic disease or atopic dermatitis, comprising the step of administering or taking a composition comprising Jasmone or a pharmaceutically acceptable salt thereof as an active ingredient.
  • the present invention provides for the prevention or treatment of allergic diseases or atopic dermatitis of a composition comprising Jasmone or a pharmaceutically acceptable salt thereof as an active ingredient.
  • the composition comprising jasmine as an active ingredient of the present invention has an effect of improving atopic dermatitis due to an allergic reaction, and can be used as a composition for preventing or treating various allergic diseases by reducing an inflammatory response.
  • the composition of the present invention has a skin regeneration effect, it can be usefully used as a wound healing drug or functional cosmetic use for skin regeneration.
  • IL-4, IL-13 and TNF- ⁇ inflammatory cytokine-related molecules
  • Jasmon each value is 3 times average obtained from 3 independent wells
  • ⁇ SEM the letters on the bars show statistically significant differences at P ⁇ 0.05
  • FIG. 2 is a graph showing the expression change of inflammatory cytokine-related molecules (IL-1 ⁇ , IL-6 and IL-8) in Jasmon-treated keratinocytes (each value is 3 times obtained from 3 independent wells) Mean ⁇ SEM; the letters on the bars show statistically significant differences at P ⁇ 0.05).
  • IL-1 ⁇ , IL-6 and IL-8 inflammatory cytokine-related molecules
  • the present inventors note that Jasmon relieves atopic symptoms and notes the expression of IL-4, IL-13, TNF- ⁇ , IL-1 ⁇ , IL-6 or IL-8, inflammatory cytokines secreted by the immune response of cells. By confirming the reduction, the present invention was completed.
  • the present invention provides a composition for preventing or treating allergic diseases or atopic dermatitis comprising Jasmone or a salt thereof as an active ingredient.
  • Jasmon is contained in plants such as Jasmin and Yarrow, and is also called cis-jasmone.
  • the structural formula of Jasmon is C 11 H 16 O, the molecular weight is 164.248, and is represented by the following Chemical Formula 1.
  • Jasmon is listed in the Food and Drug Administration (FDA) and Korea Food and Drug Administration (KFDA) food additive database as a substance that can be used as a flavoring agent, and is safe as a food additive to Joint FAO/WHO Expert Committe on Food Additives (JECFA). Approved.
  • Jasmon Physiological activity and general functions of Jasmon have been reported to help calcium absorption. It has been reported that when the jasmon is treated with the microsomes of the skeletal muscle of the dog, the calcium absorption rate of the microsomes is increased and the content is also increased. It was reported that the LD 50 value of Jasmon was over 5,000 mg/kg when administered orally to rats.
  • the jasmon of the present invention may include jasmon hydrate, jasmon derivative, and the like within a range having the same efficacy as that of jasmon, and may also include a solvent compound or a stereoisomer thereof.
  • the method for obtaining the jasmon is not particularly limited, and it may be used to separate it from a plant containing the jasmon, chemically synthesized using a known manufacturing method, or commercially available one.
  • the terms "cosmetic acceptable salt”, “food acceptable salt”, “pharmaceutically acceptable salt” or “salt thereof” may be an acid addition salt formed by a free acid.
  • Acid addition salts can be prepared by conventional methods, for example, by dissolving the compound in an excess of an aqueous acid solution and precipitating the salt using a water miscible organic solvent such as methanol, ethanol, acetone or acetonitrile.
  • a water miscible organic solvent such as methanol, ethanol, acetone or acetonitrile.
  • the same molar amount of the compound and acid or alcohol in water eg, glycol monomethyl ether
  • the mixture is evaporated to dryness, or the precipitated salt can be suction filtered.
  • an inorganic acid or an organic acid can be used as the free acid.
  • the inorganic acid may be used hydrochloric acid, phosphoric acid, sulfuric acid, nitric acid, tartaric acid, etc., these may be used alone or in combination of two or more.
  • Non-limiting examples of the organic acid are methanesulfonic acid, p-toluenesulfonic acid, acetic acid, trifluoroacetic acid, maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, manderic acid, propionic acid (propionic acid) acid, citric acid, lactic acid, glycolic acid, gluconic acid, galacturonic acid, glutamic acid, glutaric acid, glucuronic acid (glucuronic acid), aspartic acid, ascorbic acid, carbonic acid, vanic acid, hydroiodic acid, and the like can be used. These may be used alone or in combination of two or more.
  • the jasmine may be used to make a metal salt that is cosmetically or foodologically acceptable using a base.
  • Alkali metal or alkaline earth metal salts can be obtained, for example, by dissolving the compound in an excess of an alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering the compound salt inexpensively, and then evaporating and drying the filtrate.
  • the metal salt is particularly preferably prepared sodium, potassium or calcium salt, but is not limited thereto.
  • the corresponding silver salt can be obtained by reacting an alkali metal or alkaline earth metal salt with a suitable silver salt (for example, silver nitrate).
  • the salt of jasmon may include all salts of acidic or basic groups that may be present in the compound of jasmon, unless otherwise indicated.
  • the salt of jasmine may include sodium, calcium, and potassium salts of hydroxy groups
  • other cosmetically acceptable salts of amino groups include hard bromide, sulfuric acid, hydrogen sulfate, phosphate, hydrogen phosphate, Dihydrogen phosphate, acetate, succinate, citrate, tartrate, lactate, mandelate, methanesulfonate (mesylate) and p-toluenesulfonate (tosylate) salts, etc., and preparation of salts known in the art It can be prepared through a method.
  • allergic disease refers to a disease caused by an allergic reaction (allergy) in which the immune response in the body to an external antigen is excessive, specifically, edema, hypersensitivity (anaphylaxis), allergic rhinitis (allergic One or more diseases selected from the group consisting of rhinitis, asthma, allergic conjunctivitis, allergic dermatitis, contact dermatitis, urticaria, pruritus, insect allergy, food allergy and drug allergy However, it is not limited thereto.
  • Atopic dermatitis in the present invention is one of allergic diseases, it is a skin disease accompanied by symptoms such as itching, dry skin, increased skin thickness, characteristic eczema.
  • the pharmaceutical composition for preventing or treating an allergic disease or atopic dermatitis is not particularly limited in its content if it contains jasmine or a pharmaceutically acceptable salt thereof, but preferably the dose of jasmine is 0.1 ⁇ M to 1000 ⁇ M, but is not limited thereto.
  • the jasmon is less than the concentration range, there is a problem that it is difficult to exert a desirable preventive or therapeutic effect, and if the jasmon exceeds the concentration range, there may be a concern about toxicity, including cytotoxicity.
  • the pharmaceutical composition for preventing or treating allergic diseases or atopic dermatitis is an oral dosage form, an external preparation, a suppository, and the like according to a conventional method, such as powder, granule, tablet, capsule, suspension, emulsion, syrup, aerosol, etc. It may be formulated and used in the form of a sterile injectable solution, and may include suitable carriers, excipients, or diluents commonly used in the manufacture of pharmaceutical compositions for formulation.
  • carrier or excipient or diluent examples include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, and crude Various compounds or mixtures including vaginal cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
  • diluents or excipients such as fillers, weights, binders, wetting agents, disintegrants, surfactants, etc., which are usually used.
  • Solid preparations for oral administration may be prepared by mixing at least one excipient such as starch, calcium carbonate, sucrose or lactose, gelatin, etc. with the jasmine.
  • excipients such as starch, calcium carbonate, sucrose or lactose, gelatin, etc.
  • lubricants such as magnesium stearate and talc may be used in addition to simple excipients.
  • Liquid preparations for oral use include suspensions, liquid solutions, emulsions, syrups, etc.
  • various excipients such as wetting agents, sweeteners, fragrances, and preservatives, may be included. .
  • Formulations for parenteral administration include sterile aqueous solutions, non-aqueous agents, suspensions, emulsions, lyophilized preparations, and suppositories.
  • Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate.
  • injectable esters such as ethyl oleate.
  • As a base for suppositories witepsol, macrogol, tween 61, cacao butter, laurin butter, and glycerol gelatin can be used.
  • the preferred dosage of the pharmaceutical composition for the prevention or treatment of allergic disease or atopic dermatitis varies depending on the patient's condition, weight, degree of disease, drug form, administration route and duration, but may be appropriately selected by those skilled in the art. Can. However, for a desired effect, it can be administered at 0.0001 to 2,000 mg/kg per day, preferably at 0.001 to 2,000 mg/kg per day. Administration may be administered once a day, or may be divided into several times. However, the scope of the present invention is not limited by the dosage.
  • the pharmaceutical composition for preventing or treating allergic diseases or atopic dermatitis can be administered to various mammals, such as rats, mice, livestock, and humans. All modes of administration can be administered, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dura mater or intracerebroventricular injection.
  • composition comprising the active ingredient according to the present invention reduces allergic diseases by reducing the expression of IL-4, IL-13, TNF- ⁇ , IL-1 ⁇ , IL-6 or IL-8, which is excessively secreted due to an immune response or It can improve and prevent atopic dermatitis symptoms.
  • IL-4, IL-13, TNF- ⁇ , IL-1 ⁇ , IL-6 and IL-8 which are inflammatory cytokines secreted by the immune response of cells.
  • the present invention provides a composition for preventing or improving allergic disease or atopic dermatitis comprising Jasmone or a salt thereof as an active ingredient.
  • composition for preventing or improving allergic disease or atopic dermatitis of the present invention may be a health functional food composition, a cosmetic composition, or a fragrance composition.
  • the term "health functional food” refers to food prepared and processed in the form of tablets, capsules, powders, granules, liquids and pills, etc. using ingredients or ingredients having useful functionality for the human body.
  • the term'functional' refers to obtaining a useful effect for health use, such as regulating nutrients or physiological effects on the structure and function of the human body.
  • the health functional food of the present invention can be manufactured by a method conventionally used in the art, and at the time of manufacture, it may be prepared by adding raw materials and ingredients commonly added in the art.
  • the formulation of the health functional food can also be prepared without limitation as long as the formulation is recognized as a health functional food.
  • the health functional food composition of the present invention has the advantage that there is no side effect or the like that may occur when taking the drug for a long time by using food as a raw material, unlike a general drug, and it has excellent portability, and promotes an anti-allergic effect or atopic dermatitis symptom relief effect. It can be consumed as a supplement to prescribe.
  • the jasmon when used as an additive in the health functional food, it can be added as it is or used with other foods or food ingredients, and is common It can be used as appropriate depending on the method.
  • the mixing amount of the active ingredient can be appropriately determined according to each purpose of use such as prevention, health or treatment.
  • the formulation of the dietary supplement can be in the form of powders, granules, pills, tablets, capsules, as well as in the form of regular food or beverages.
  • the type of the food is not particularly limited, and examples of foods to which the substance can be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, and ice cream. , Various soups, beverages, teas, drinks, alcoholic beverages and vitamin complexes, and may include all foods in the ordinary sense.
  • the jasmon in general, in the manufacture of food or beverage, may be added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less based on 100 parts by weight of the raw material.
  • the amount in the case of long-term intake for the purpose of health and hygiene or for the purpose of health control, the amount may be below the above range, and also the present invention has no problem in terms of safety in terms of using fractions from natural products. It can also be used in the above amount.
  • the beverage may contain various flavoring agents or natural carbohydrates, etc., as additional components, like a conventional beverage.
  • the natural carbohydrates described above may be monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, sugar alcohols such as xylitol, sorbitol, and erythritol.
  • sweetener natural sweeteners such as taumatin and stevia extract, and synthetic sweeteners such as saccharin and aspartame can be used.
  • the ratio of the natural carbohydrate may be about 0.01 ⁇ 0.04 g per 100 mL of the beverage according to the present invention, preferably about 0.02 ⁇ 0.03 g.
  • the health functional food for prevention or improvement of allergic disease or atopic dermatitis includes various nutrients, vitamins, electrolytes, flavors, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, and protective colloids It may contain thickening agents, pH adjusting agents, stabilizers, preservatives, glycerin, alcohol, carbonic acid used in carbonated beverages.
  • the health functional food composition for preventing or improving allergic disease or atopic dermatitis of the present invention may contain natural fruit juice, fruit juice beverage, and flesh for the production of vegetable beverage. These ingredients may be used independently or in combination. The ratio of these additives is not limited, but is generally selected from 0.01 to 0.1 parts by weight compared to 100 parts by weight of the functional food of the present invention.
  • the term "cosmetic composition” used in the present invention is a composition comprising the compound, the formulation may be in any form.
  • the cosmetic product prepared using the composition includes nutrient cream, eye cream, massage cream, creams such as cleansing cream, packs, lotions such as nutrient lotions, essences, softening lotion, and lotion such as nutrient makeup They are powders, powders, foundations and makeup bases, and can be manufactured and commercialized in any of these forms to achieve the object of the present invention, and are not limited to the above examples.
  • the cosmetic composition according to the present invention can be formulated in a conventional cosmetic manufacturing method.
  • the cosmetic of the present invention is a skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nutrition lotion, massage cream, nutrition cream, moisture cream, hand cream, essence, pack, mask pack, mask sheet , Soap, shampoo, cleansing foam, cleansing lotion, cleansing cream, body lotion, body cleanser, emulsion, press powder, rust powder, and may have any one selected from the group consisting of eye shadow.
  • the cosmetic composition of the present invention may include other additives such as excipients, carriers, etc. in addition to Jasmon or a salt thereof, and it is possible to apply and mix the usual ingredients to be blended into a general skin cosmetic as necessary.
  • the cosmetic composition of the present invention may further include a transdermal penetration enhancer.
  • transdermal penetration enhancer is a composition that allows the desired component to penetrate into the vascular cells of the skin with a high absorption rate.
  • other phospholipid components, liposome components, and the like used in lecithin cosmetics are included, but are not limited thereto.
  • oils that can be mainly used as the oil component. More specifically, mineral oil, cyclomethicone, squalane, octyldodecyl myristate, olive oil, Vitis vinifera seed oil, macadamia nut oil, glyceryl octanoate, castor oil, ethylhexyl isononanoate, dime Chicon, cyclopentasiloxane and sunflower seed oil can be used.
  • a surfactant such as nonionic surfactants, anionic surfactants, cationic surfactants, amphoteric surfactants, and phospholipids can be used as such surfactants.
  • sorbitan sesquinolate polysorbate 60 , Glyceryl stearate, lipophilic glyceryl stearate, sorbitan oleate, sorbitan stearate, die-cetyl phosphate, sorbitan stearate/ sucrose cocoate, glyceryl stearate/polyethylene glycol-100 Stearate, ceteareth-6 oleate, arachidyl alcohol/ behenyl alcohol/arachidyl glucoside, polypropylene glycol-26-butes-26/ polyethylene glycol-40 hydrogenated castor oil, etc.
  • alcohols having 12 to 20 carbon atoms such as cetyl alcohol, stearyl alcohol, octyldodecanol, and isostearyl alcohol, may be used alone or in combination of one or more.
  • the aqueous phase component may further add 0.001 to 5% by weight of one or more thickeners such as carbomer, xanthan gum, bentonite, magnesium aluminum silicate, cellulose gum, dextrin palmitate, etc. in order to adjust the viscosity or hardness of the aqueous phase.
  • thickeners such as carbomer, xanthan gum, bentonite, magnesium aluminum silicate, cellulose gum, dextrin palmitate, etc.
  • composition of the present invention if necessary, pharmaceutical ingredients such as higher fatty acids, vitamins, sunscreens, and antioxidants (butyl hydroxyanisole, propyl gallic acid, elisoric acid, tocopheryl acetate, butylated hydroxy) Toluene, etc.), preservatives (methylparaben, butylparaben, propylparaben, phenoxyethanol, imidazolidinylurea, chlorphenesin, etc.), colorants, pH adjusters (triethanolamine, citric acid, citric acid, sodium citrate, malic acid, Sodium malate, phthalic acid, sodium phthalate, succinic acid, sodium succinate, sodium hydroxide, sodium hydrogen phosphate, etc., moisturizers (glycerin, sorbitol, propylene glycol, butylene glycol, hexylene glycol, diglycerin , Betaine, glycereth-26, methylglucose-20,
  • the cosmetic composition of the present invention further includes a substance capable of supplementally providing essential nutrients to the skin, and may preferably contain auxiliaries including, but not limited to, natural, cosmetic, or herbal medicines. have.
  • the effective content of Jasmon or its cosmetically acceptable salt in the cosmetic composition of the present invention is not particularly limited, and may be included in 0.0001 to 20% by weight based on the total weight of the composition. In cosmetics, less than 0.0001% by weight of jasmon or a salt thereof may have no wrinkle improvement effect due to a small amount thereof, and more than 20% by weight of jasmon or a salt thereof may exhibit known toxicity.
  • perfume composition of the present invention may be blended in external skin preparations such as perfumes, cosmetics, bathing agents, foods, pharmaceuticals, etc., and the blending amount is appropriately selected in order to achieve the desired effect according to conventional techniques in the art. It can be combined.
  • the formulation of the perfume composition of the present invention is not particularly limited, but may be any one selected from powder, granule, liquid spray, solid and gel type formulations.
  • the fragrance composition includes cosmetic products containing perfume, soap cleaning products containing bath soap, indoor cleaning products including glass cleaner, fragrance products including car air fresheners, bath products including herbal bath products, and stationery It can be used to manufacture fragrance products, environmental products including office fragrances, or industrial products containing synthetic resins.
  • the perfume composition of the present invention is based on the total weight of the perfume composition, the active ingredient of Jasmon, 0.00001% to 10% by weight, preferably 0.00001% to 1.0% by weight, depending on the product form in which the perfume composition of the present invention is embodied It may contain in the range of weight%, more preferably 0.00001% by weight to 0.5% by weight.
  • the product form in which the fragrance composition is embodied includes soap, cosmetics, bathing agent, aroma oil, etc., specifically, body lotion, shampoo, hair rinse, hair conditioner, hair treatment, antiperspirant, skin lotion, skin cream, deodorant , Perfume (spray or fumigant), lipstick, lip balm, bath, and the like, but is not limited to these.
  • These products may contain various additives such as blood circulation accelerators, anti-inflammatory agents, moisturizers, astringents, inorganic salts, organic salts, oily ingredients, surfactants, herbal medicines, pigments, fragrances, sulfur, interstitial deposits, fungicides, etc. .
  • the fragrance composition of the present invention will be generally used as an external preparation for skin in cosmetic formulations such as makeup products, skin lotions, and skin creams.
  • cosmetic formulations such as makeup products, skin lotions, and skin creams.
  • it may contain ingredients commonly used in these cosmetic formulations.
  • the perfume composition of the present invention is preferably used as being incorporated into a bathing agent in that the active ingredient Jasmon has an atopic dermatitis improving activity.
  • the active ingredient may be included in the range of 0.00001 to 1% by weight, more preferably 0.0001 to 0.1% by weight, based on the total weight of the bathing agent.
  • the bathing agent may be used in a concentration of 0.015 to 15 ppm in the bath water.
  • Bathing agents may contain inorganic salts, organic acids, oily components, etc. in addition to the active ingredients of the perfume composition of the present invention.
  • sodium chloride, sodium hydrogen carbonate, sodium carbonate, borax, sodium sulfate, sodium sulfide, sodium sesquicarbonate, sodium nitrate, sodium thiosulfate, sodium polyphosphate, sodium phosphate, calcium oxide, magnesium oxide, calcium carbonate, magnesium carbonate, potassium chloride, sulfide Potassium and the like can be exemplified, and these may be used alone or as a mixture of two or more.
  • These inorganic salts may be added to the bathing agent in an amount of 5% by weight or more, preferably 10% by weight or more based on the total weight of the bathing agent.
  • succinic acid fumaric acid, malic acid, tartaric acid, citric acid, benzoic acid, etc.
  • these organic acids can be added to the bathing agent in a range of 0.1 to 50% by weight based on the total weight of the bathing agent.
  • oily component examples include wax, hydrocarbons, higher fatty acids, higher alcohols, esters, and silicone oils.
  • Bathing agents may also contain other ingredients commonly used in the art.
  • these components include inorganic acids such as boric acid, metasilicic acid, and silicic anhydride; Medicinal herb powder such as fennel, ginkgo, ginger, citrus peel, Valerian root, peppermint, ginseng, and oats; Natural pigments that have been found to be harmless to the human body, such as coal tar dyes, chlorophyll, riboflavin, saffflower, and anthraquinone; Vitamins such as vitamin A, vitamin C, vitamin D, and vitamin E; Sulfur, mica powder, white clay powder, ocher powder, rice bran carbide, disinfectant, preservative, and the like.
  • inorganic acids such as boric acid, metasilicic acid, and silicic anhydride
  • Medicinal herb powder such as fennel, ginkgo, ginger, citrus peel, Valerian root, peppermint, ginseng, and oats
  • Natural pigments that have been found
  • bathing agents can be prepared in any form such as granules, tablets, liquids, powders, and the like.
  • the present invention provides a pharmaceutical composition, quasi-drug composition and cosmetic composition for promoting skin wound healing or skin regeneration, which includes Jasmone or a pharmaceutically acceptable salt thereof as an active ingredient.
  • Mast cells (rat basophilic leukemia cell line, RBL-2H3) were purchased from ATCC (Manassas, VA, USA). Dulbecco modified eagle medium (DMEM), including 10% heat-inactivated feta bovine serum (FBS) (Gibco BRL, USA) and 1% penicillin and streptomycin (Gibco BRL, USA) (Gibco BRL, USA) Cells were cultured in culture. Cells were cultured and tested under conditions of 37°C and 5% CO 2 . Mast cells were suspended in DMEM containing 10% FBS, and then divided into 6 well plates (Corning, USA) to have a cell count of 1 ⁇ 10 6 cells/ml.
  • DMEM Dulbecco modified eagle medium
  • FBS heat-inactivated feta bovine serum
  • penicillin and streptomycin Gabco BRL, USA
  • the cells were sensitized with anti DNP (dinitrophenyl)-IgE (30 ng/ml) and cultured in a 37°C, 5% CO 2 incubator for 24 hours. After washing twice with PBS (phosphate buffered saline), DNP-HSA (dinitrophenylated human serum albumin; 10 ⁇ g/ml) was treated for 4 hours to induce an immune response.
  • anti-DNP (dinitrophenyl)-IgE treatment was performed to treat mast cells cultured for 24 hours with 100 ⁇ M of Jasmon and incubated for 1 hour, followed by an immune response with DNP-HSA. Induced.
  • Keratinocytes human keratinocyte cell line, HaCaT
  • ATCC Manassas, VA, USA
  • Cells were cultured using DMEM culture medium containing 10% fetal bovine serum (FBS) and antibiotics.
  • FBS fetal bovine serum
  • the culture vessel used a 75T-flask and a 6-well plate, and cultured in a 37°C incubator supplied with 5% CO2.
  • the culture medium was changed every 3-4 days, and when the cells proliferated excessively, they were passaged.
  • Dispensed HaCaT cells (5 ⁇ 10 5 /well) were cultured for 24 hours, and then washed with PBS.
  • TMEM- ⁇ tumor necrosis factor- ⁇
  • IFN- ⁇ interferon gamma
  • RT-PCR was reacted at 45°C for 30 minutes and 94°C for 5 minutes using one-step RT-PCR PreMixkit (iNtRON Biotechnology, Korea), then denatured at 94°C for 30 seconds, and then at 55°C for 30 seconds. After annealing, and then repeating the cycle of extending 32 times at 72°C for 1 minute, the final extension was performed at 72°C for 5 minutes and PiQ SYBR green supermix (Bio-Rad) And CFX ConnectTM Real-Time PCR Detection System (Bio-Rad) was used to perform quantitative PCR, wherein the primer sequences used are as shown in [Table 1].
  • RT-PCR PreMixkit iNtRON Biotechnology, Korea
  • the above ingredients were mixed and filled in an airtight fabric to prepare a powder.
  • tablets were prepared by tableting according to a conventional tablet manufacturing method.
  • the capsules were prepared by filling the gelatin capsules according to a conventional method for preparing capsules.
  • Dissolve the above components by adding each component to purified water according to a conventional manufacturing method, add an appropriate amount of lemon flavor, adjust purified water to 100 mL, and sterilize to fill the brown bottle to prepare a liquid.
  • Vitamin A Acetate 70 ⁇ g
  • Vitamin B 1 0.13 mg
  • Vitamin B 2 0.15 mg
  • Vitamin B 6 0.5 mg
  • Vitamin B 12 0.2 ⁇ g
  • composition ratio of the vitamin and mineral mixture is a composition suitable for a relatively healthy food in a preferred embodiment, the composition ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for preparing a healthy food.
  • Granules can be prepared and used in the preparation of healthy food compositions according to conventional methods.
  • Vitamin A 0.2 g
  • Vitamin B1 0.25 g
  • Vitamin B2 0.3 g
  • the resulting solution is filtered, obtained in a sterilized 2 liter container, sealed and sterilized, then stored in a refrigerator and then stored in the present invention. Used in the manufacture of health drink compositions.
  • composition ratio is a mixture of components suitable for preference beverages in a preferred embodiment, the composition ratio may be arbitrarily modified according to regional and ethnic preferences such as demand class, country of use, and usage.
  • the above blending ratio is a composition in which a component suitable for nutrient longevity is mixed in a preferred embodiment, but the blending ratio may be arbitrarily modified, and may be prepared according to a manufacturing method in the general cosmetic field.
  • the above mixing ratio is a composition suitable for a relatively soft cosmetic composition in a preferred embodiment, but the mixing ratio may be arbitrarily modified, and may be prepared according to a manufacturing method in the general cosmetic field.
  • the above blending ratio is a composition in which a component suitable for a nutrient cream is mixed in a preferred embodiment, but the blending ratio may be arbitrarily modified, and may be prepared according to a manufacturing method in the general cosmetic field.
  • the above mixing ratio is a composition suitable for a relatively suitable massage cream in a preferred embodiment
  • the mixing ratio may be arbitrarily modified, and may be prepared according to a manufacturing method in the general cosmetic field.
  • the above-mentioned compounding ratio is a composition in which the components suitable for the pack are mixed in a preferred embodiment, the compounding ratio may be arbitrarily modified, and may be prepared according to a manufacturing method in the general cosmetic field.
  • the compounding ratio is a composition in which a component suitable for a gel is mixed in a preferred embodiment, the compounding ratio may be arbitrarily modified, and may be prepared according to a manufacturing method in the general cosmetic field.
  • the above blending ratio is a composition suitable for a relatively cosmetic composition in a preferred embodiment, but can be applied to cosmetics for various uses including other color cosmetics. It can be used for manufacturing ointment furnaces, and the mixing ratio can be arbitrarily modified according to regional and ethnic preferences such as demand class, country of demand, and usage.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Birds (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne une composition antiallergique, de soulagement de dermatite atopique ou de régénération de la peau contenant de la jasmone en tant que principe actif et, plus particulièrement, une composition pour prévenir ou traiter des maladies allergiques ou une dermatite atopique et une composition pour la cicatrisation de plaies cutanées ou pour favoriser la régénération de la peau, les deux contenant, en tant que principe actif, de la jasmone ou un sel pharmaceutiquement acceptable correspondant.
PCT/KR2019/017488 2018-12-20 2019-12-11 Composition antiallergique, de soulagement de dermatite atopique ou de régénération de la peau contenant de la jasmone en tant que principe actif Ceased WO2020130478A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2018-0166596 2018-12-20
KR1020180166596A KR101984195B1 (ko) 2018-12-20 2018-12-20 자스몬을 유효성분으로 포함하는 항알러지, 아토피 피부염 개선, 또는 피부 재생용 조성물

Publications (1)

Publication Number Publication Date
WO2020130478A1 true WO2020130478A1 (fr) 2020-06-25

Family

ID=66675539

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2019/017488 Ceased WO2020130478A1 (fr) 2018-12-20 2019-12-11 Composition antiallergique, de soulagement de dermatite atopique ou de régénération de la peau contenant de la jasmone en tant que principe actif

Country Status (2)

Country Link
KR (1) KR101984195B1 (fr)
WO (1) WO2020130478A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101984195B1 (ko) * 2018-12-20 2019-05-30 주식회사 보타닉센스 자스몬을 유효성분으로 포함하는 항알러지, 아토피 피부염 개선, 또는 피부 재생용 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58118536A (ja) * 1982-01-08 1983-07-14 Mitsui Toatsu Chem Inc ジヤスモン類の製造方法
KR20100080438A (ko) * 2008-12-30 2010-07-08 로레알 모노사카라이드 및 각질박리제 조합 및 그 미용적 용도
KR20160096903A (ko) * 2015-02-06 2016-08-17 (주)아모레퍼시픽 귤꽃류의 향취를 재현한 향료 조성물
KR20170110902A (ko) * 2016-03-24 2017-10-12 주식회사 엘지생활건강 향료 조성물
KR101984195B1 (ko) * 2018-12-20 2019-05-30 주식회사 보타닉센스 자스몬을 유효성분으로 포함하는 항알러지, 아토피 피부염 개선, 또는 피부 재생용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030206893A1 (en) * 2002-05-06 2003-11-06 Sohail Malik Cell proliferating agents
US20040185075A1 (en) * 2003-01-31 2004-09-23 Maria Dalko Use of at least one (dihydro)jasmonic acid derivative for treating dry skin
UA98778C2 (ru) * 2006-12-12 2012-06-25 Сунев Фарма Солюшн Лимитед Корпорейт Местный состав для предупреждения ампутации инфицированных конечностей и способ его получения, местный ранозаживляющий состав и способ его получения и применения
US20120083529A1 (en) * 2009-06-09 2012-04-05 Sepal Pharma Ltd Use of jasmonate ester derivatives for treating benign hyperproliferative skin disorders
KR101783306B1 (ko) * 2015-12-16 2017-09-29 경북대학교병원 ＰＤＫｓ 억제제를 유효성분으로 함유하는 알러지성 질환의 예방 또는 치료용 약학적 조성물
KR101777992B1 (ko) * 2017-04-03 2017-09-12 연세대학교 산학협력단 자스몬(Jasmone) 또는 이의 염을 유효성분으로 함유하는 피부주름 개선, 보습, 탄력증진, 각질제거, 홍반억제 또는 피부광노화 개선용 조성물
KR20180128602A (ko) 2017-05-24 2018-12-04 한남대학교 산학협력단 나복근 즙을 유효성분으로 함유하는 아토피 피부염의 예방, 개선 또는 치료용 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58118536A (ja) * 1982-01-08 1983-07-14 Mitsui Toatsu Chem Inc ジヤスモン類の製造方法
KR20100080438A (ko) * 2008-12-30 2010-07-08 로레알 모노사카라이드 및 각질박리제 조합 및 그 미용적 용도
KR20160096903A (ko) * 2015-02-06 2016-08-17 (주)아모레퍼시픽 귤꽃류의 향취를 재현한 향료 조성물
KR20170110902A (ko) * 2016-03-24 2017-10-12 주식회사 엘지생활건강 향료 조성물
KR101984195B1 (ko) * 2018-12-20 2019-05-30 주식회사 보타닉센스 자스몬을 유효성분으로 포함하는 항알러지, 아토피 피부염 개선, 또는 피부 재생용 조성물

Also Published As

Publication number Publication date
KR101984195B1 (ko) 2019-05-30

Similar Documents

Publication Publication Date Title
WO2013019049A1 (fr) Complexe comprenant des glycosides de stéviol ou de la racine de réglisse et matière faiblement soluble
WO2018004141A1 (fr) Composition ayant pour effet d'améliorer l'hydratation de la peau, d'exfolier la peau, d'améliorer l'élasticité de la peau, d'inhiber l'érythème, d'atténuer les rides cutanées ou d'atténuer le photovieillissement cutané, contenant, en tant qu'ingrédient actif, un ou plusieurs composés choisis dans le groupe constitué du cimène, de l'acide béhénique, du 2-méthoxynaphtalène, du thymol et de leurs sels
WO2020091440A9 (fr) Composition permettant d'améliorer l'endommagement de la barrière cutanée et/ou de soulager l'inflammation cutanée, contenant de l'acide 3,5-dicaféoylquinique en tant que principe actif
WO2010087577A2 (fr) Utilisation d'extrait de thymus capitatus, d'extrait de satureja hortensis, ou de carvacrol pour traiter des maladies métaboliques
WO2022250313A1 (fr) Composition d'hydratation de la peau, favorisant la régénération de la peau, et le traitement des plaies, comprenant de l'extrait de fleur d'aloe vera, ou de l'extrait de fleur d'aloe vera et des polysaccharides d'aloe vera, comme ingrédient(s) actif(s)
WO2020145619A1 (fr) Composition pour la prévention des allergies, le soulagement de la dermatite atopique ou la régénération de la peau, contenant, en tant que principe actif, un undécane ou un undécanal
WO2020085826A1 (fr) Composition pour soulager une irritation de la peau induite par des facteurs de pollution environnementaux ou pour la protection de la peau, contenant comme principe actif un extrait de noix de muscade ou du macelignane
WO2020218720A1 (fr) Composition pour la prévention ou le traitement de troubles musculaires ou l'amélioration de la fonction musculaire, contenant un extrait de leonurus japonicus ou de la léonurine
WO2020218890A1 (fr) Composition consistant en un extrait d'actinidia polygama destiné à attenuer des lésions cutanées ou hydrater la peau
WO2023113431A1 (fr) Nouvelle souche et son utilisation
WO2020067748A1 (fr) Composition ayant un effet anti-stress, antidépresseur ou anxiolytique comprenant au moins un composé choisi dans le groupe constitué par l'undécanal, le dodécanal, et des sels pharmaceutiquement acceptables de ces derniers en tant que principe actif
WO2020130478A1 (fr) Composition antiallergique, de soulagement de dermatite atopique ou de régénération de la peau contenant de la jasmone en tant que principe actif
EP4125983A1 (fr) Composition pharmaceutique orale comprenant un extrait d'herbes combinées comprenant du longanae arillus pour le traitement ou le soulagement d'une maladie inflammatoire et son utilisation
WO2018070705A1 (fr) Composition pour prévenir ou traiter des maladies musculaires, contenant, en tant que principe actif, de la diosmine ou un sel pharmaceutiquement acceptable de cette dernière
WO2018062820A1 (fr) Composition visant à prévenir la chute des cheveux et à en favoriser la pousse, comprenant un phytoœstrogène en tant que principe actif
WO2021080297A1 (fr) Composition contenant un extrait de fleur d'onagre en tant que principe actif pour prévenir ou traiter l'obésité ou des syndromes métaboliques ainsi induits
WO2010143825A2 (fr) Agent antiarthritique à l'aide de cyathula officinalis
WO2021167120A1 (fr) Composition antiallergique, pour l'atténuation d'une dermatite atopique ou la régénération de la peau, contenant de l'acétate de guaiyle utilisé comme principe actif
WO2020256380A1 (fr) Composition de blanchiment de la peau comprenant de la carvone ou un sel de celle-ci en tant que principe actif
WO2021167121A1 (fr) Composition pour la prévention de l'allergie, l'atténuation d'une dermatite atopique ou la régénération de la peau, comprenant un nonane utilisé comme principe actif
WO2021034080A1 (fr) Composition pour la prévention ou le traitement d'une maladie allergique ou de la dermatite atopique comprenant de la carvone ou un sel associé comme principe actif
WO2010041908A2 (fr) Nouvelle utilisation d'un dérivé de panduratine ou d'un extrait de boesenbergia pandurata
WO2019083286A2 (fr) Composition contenant de l'irone comme principe actif pour prévenir la chute des cheveux ou stimuler la repousse des cheveux
WO2019172566A1 (fr) Agent anti-stress, composition d'agent anti-anxiété ou antidépresseur contenant de l'ionone en tant que principe actif
WO2019083288A1 (fr) Composition comprenant de l'acide subérique en tant que principe actif pour prévenir la chute des cheveux ou activer la pousse des cheveux

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19900247

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19900247

Country of ref document: EP

Kind code of ref document: A1